1975
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvivalADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY
Devita V, Canellos G, Chabner B, Schein P, Hubbard S, Young R. ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY. The Lancet 1975, 305: 248-250. PMID: 46388, DOI: 10.1016/s0140-6736(75)91142-3.Peer-Reviewed Original ResearchConceptsAdvanced diffuse histiocytic lymphomaDiffuse histiocytic lymphomaCombination chemotherapyHistiocytic lymphomaPatients treated with radiotherapyTreated with combination chemotherapySurvival free of diseaseEvidence of tumorFree of diseaseRecurrence of tumorReticulum-cell sarcomaDefinition of cureModern drug treatmentComplete remissionPartial respondersNon-respondersDrug treatmentPatientsSurvival dataLymphomaRemissionChemotherapyNitrogen mustardTumorTreatment
1974
Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance
Mason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaPlatelet countGranulocytic leukemiaClinical significanceOccurrence of thrombocytosisElevated platelet countThrombohemorrhagic complicationsUntreated patientsMedian durationShorter survivalBlastic crisisNormal countsPatientsSubsequent courseThrombocytosisLeukemiaCountEntire courseGroupCourseComplicationsClinicIncidenceDiagnosisPotential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma. Blood 1974, 43: 181-189. PMID: 4589318, DOI: 10.1182/blood.v43.2.181.181.Peer-Reviewed Original ResearchConceptsComplete remissionMedian survivalCombination chemotherapyHodgkin's lymphomaExtended disease-free survivalDisease-free survivalImproved median survivalNon-Hodgkin lymphomaMOPP chemotherapyMedian durationFurther therapyNodular histologyHistologic subgroupsDiffuse histologyHistologic categoriesNodular patternAggressive subgroupClinical validityLymphomaAdvanced stageRemissionChemotherapyEntire groupPatientsSignificant differences
1973
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Sherins R, DeVita V. Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Annals Of Internal Medicine 1973, 79: 216-20. PMID: 4580112, DOI: 10.7326/0003-4819-79-2-216.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsBiopsyBurkitt LymphomaCyclophosphamideGerm CellsHodgkin DiseaseHumansLibidoLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedNitrogen Mustard CompoundsPrednisoneProcarbazineRemission, SpontaneousSertoli CellsSpermatogenesisSpermatozoaTestisTime FactorsVincristine
1972
Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy
Arseneau J, Sponzo R, Levin D, Schnipper L, Bonner H, Young R, Canellos G, Johnson R, DeVita V. Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy. New England Journal Of Medicine 1972, 287: 1119-1122. PMID: 5082192, DOI: 10.1056/nejm197211302872204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellCyclophosphamideDrug-Related Side Effects and Adverse ReactionsFemaleFibrosarcomaFollow-Up StudiesHead and Neck NeoplasmsHodgkin DiseaseHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsNeoplasms, Radiation-InducedNitrogen Mustard CompoundsPrednisoneProcarbazineRadiotherapyRemission, SpontaneousTime FactorsVincristineConceptsHodgkin's diseaseMalignant tumorsIntensive radiotherapyIntensive chemotherapyBiopsy-proven malignant tumorsTime of diagnosisSecond malignant tumorsRisk of developmentBasis of treatmentBasis of ageIntensive therapyCase recordsChemotherapyDiseasePatientsRadiotherapyTumorsGreater increaseSubgroupsRiskTherapyIncidenceDiagnosisCombination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
Canellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsBenzoatesFemaleHodgkin DiseaseHumansMaleMiddle AgedNitrogen Mustard CompoundsPrednisoneProcarbazineRecurrenceVincristineConceptsHodgkin's diseaseCombination chemotherapyProlonged disease-free intervalExtensive radiation therapyAdvanced Hodgkin's diseaseDisease-free intervalEnd of radiotherapyOnset of chemotherapyCombination chemotherapy programsDegree of myelosuppressionExtensive radiotherapyIntensive radiotherapyCurative intentComplete remissionExtensive diseasePrevious radiotherapyRemission rateChemotherapy programRadiation therapyDrug toxicityPatientsRadiotherapyMonthly cyclesChemotherapyDiseaseClinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original Research
1970
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease
LOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntimetabolitesAntineoplastic AgentsBenzoatesChildFemaleHodgkin DiseaseHumansLeukopeniaMaleMiddle AgedNitrogen Mustard CompoundsPrednisoneVincristineConceptsCombination chemotherapyPrior radiotherapyHodgkin's diseaseProgressive Hodgkin's diseaseStage IV diseaseRemission 1Previous therapyComplete responseNitrogen mustardPartial responseTherapy completionSystemic symptomsDrug combinationsChemotherapyPatientsDay 1Drug AdministrationRadiotherapyPrednisoneDiseasePoor toleranceVincristineCycle 1TherapyI.V.The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological disposition